Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering

Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) announced the pricing of its underwritten public offering, raising approximately $200 million. The offering includes 3,318,585 shares of common stock and pre-funded warrants. Praxis granted underwriters an option for additional shares, with the closing expected soon.
  • Praxis raised $200 million through its public offering.
  • The offering includes 3,318,585 shares of common stock and pre-funded warrants.
  • Underwriters have an option to purchase additional shares.
  • The offering is expected to close soon.
  • None.

From a financial perspective, the public offering by Praxis Precision Medicines represents a significant capital infusion, which is likely to bolster their research and development endeavors. The pricing of shares at $56.50 indicates investor confidence and a potentially strong market appetite for the company's stock. Pre-funded warrants are an interesting instrument, providing investors with a future equity stake at a slightly reduced cost, which could be appealing for those looking to invest large sums. The expected gross proceeds of $200 million, before expenses, suggest a robust funding round that could enhance the company's valuation and its ability to invest in long-term projects.

However, such offerings can dilute existing shareholders' equity, potentially leading to a short-term dip in stock price as the market adjusts to the increased share count. The underwriters' option to purchase additional shares could further dilute current stockholders but also indicates a safeguard for additional capital if the market demand is high. The impact on the stock will need to be monitored closely following the closure of the offering.

Examining the industry context, Praxis Precision Medicines is operating within the high-growth area of CNS disorder treatments, which is seeing increasing investment due to the unmet medical needs and the potential for breakthrough therapies. The capital raised could significantly accelerate Praxis' ability to compete in this space, particularly as they translate genetic insights into viable treatments. The success of this public offering could also reflect broader market trends, where investors are seeking to capitalize on innovative biotech firms with strong pipelines and clear strategies to address complex health issues.

One must consider the competitive landscape and how this capital injection positions Praxis relative to its peers. With a successful infusion of funds, Praxis could advance its clinical trials more rapidly, potentially leading to faster FDA approvals and quicker time-to-market for its therapies. The long-term implications for stakeholders include not only the prospects of financial returns but also the potential societal impact of new CNS treatments.

Within the biotech sector, the balance of excitation and inhibition in neuronal activity is a critical area of research, directly linked to a range of CNS disorders such as epilepsy, autism spectrum disorder and schizophrenia. The capital raised by Praxis Precision Medicines through this public offering could be pivotal in advancing their proprietary therapies. Given the complexity and high costs associated with CNS drug development, the substantial amount of $200 million suggests that Praxis is well-positioned to navigate through the lengthy and rigorous clinical trial phases that are characteristic of the biotech industry.

The strategic use of pre-funded warrants is noteworthy as it provides a mechanism for immediate capital increase while potentially offsetting some dilution effects. The funds are likely earmarked for clinical trials, which are the lifeblood of biotech firms' pipelines. The outcome of these trials will be critical in determining the future trajectory of the company and its ability to deliver on its promises to stakeholders and patients in need of novel therapies.

BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 3,318,585 shares of its common stock at a public offering price per share of $56.50 and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 221,238 shares of common stock at a purchase price of $56.4999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The gross proceeds from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis. All shares and pre-funded warrants in the offering are being offered by Praxis. In addition, Praxis has granted the underwriters a 30-day option to purchase up to 530,973 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 2, 2024, subject to market conditions and the satisfaction of customary closing conditions.

Piper Sandler, Guggenheim Securities and Truist Securities are acting as joint book-running managers for the offering. H.C. Wainwright & Co. and Needham & Company are acting as co-lead managers for the offering.

The offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed by Praxis with the Securities and Exchange Commission (SEC) on March 5, 2024 and declared effective by the SEC on March 12, 2024. A preliminary prospectus supplement related to the offering was filed with the SEC on March 27, 2024. The final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website at Copies of the final prospectus supplement and the accompanying base prospectus relating to the offering, when available, may be obtained from: Piper Sandler & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at; or Truist Securities, Inc., Attention: Prospectus Department, 3333 Peachtree Road NE, 9th floor, Atlanta, GA 30326, by telephone at (800) 685-4786, or by email at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Praxis’ future expectations, plans and prospects, including, without limitation, statements regarding the timing of the completion, and anticipated gross proceeds, of the offering, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “endeavor,” “estimate,” “expect,” “anticipate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would” and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995.

The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation, risks related to market conditions and other risks described in Praxis’ Annual Report on Form 10-K for the year ended December 31, 2023 and other filings made with the SEC. Although Praxis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.


How much did Praxis raise through its public offering?

Praxis raised approximately $200 million through its public offering.

What is included in the offering by Praxis?

The offering includes 3,318,585 shares of common stock and pre-funded warrants.

Do underwriters have an option for additional shares?

Yes, underwriters have a 30-day option to purchase up to 530,973 additional shares of common stock.

When is the closing of the offering expected?

The offering is expected to close soon.

Praxis Precision Medicines, Inc.


PRAX Rankings

PRAX Latest News

PRAX Stock Data

Pharmaceutical Preparation Manufacturing
United States of America

About PRAX

praxis precision medicines, inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. its lead product candidates include prax-114, an extrasynaptic-preferring gabaa receptor positive allosteric modulator that is in phase iia clinical trial for the treatment of major depressive disorder and perimenopausal depression; and prax-944, a selective small molecule inhibitor of t-type calcium channels, which is in phase iia clinical trial for the treatment of essential tremor. the company is also developing prax-562, a persistent sodium current blocker that is in phase i clinical trial to treat severe pediatric epilepsy and adult cephalgia; prax-222, an antisense oligonucleotide for patients with gain-of-function (gof) scn2a epilepsy; and kcnt1 program for the treatment of kcnt1 gof epilepsy. it has a cooperation and license agreement with rogcon inc.; a license agreement purdue neuroscience company; and a res